Portage Biotech Inc 's ROA from the fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Portage Biotech Inc 's ROA in the fourth quarter of 2025?
Portage Biotech Inc recorded a cumulative net loss of $-20 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -926.75%.

However, within the Healthcare sector 964 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4829.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Mar 31 2024) IV. Quarter
Y / Y Total Assets Change	-77.05 %	-94.53 %	-78.22 %	-74.62 %	-87.64 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-20	-53	-48	-52	-50
Return On Assets (TTM)	-926.75 %	-1304.97 %	-657.62 %	-559.61 %	-426.48 %
PRTG's Total Ranking	# 4829	#	#	#	# 4749
Total Assets (TTM) in million	2	1	2	3	10
Seq. Total Assets Change	201.49 %	-68.18 %	-32.29 %	-64.67 %	-28.17 %
Seq. Net Income Change	-	-	-	-	-

PRTG's 5 Years Annual ROA >> Back to PRTG Management Effectiveness >> Compare PRTG ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 467
Sector	# 965
Overall	# 4755

Return On Assets Statistics
High	Average	Low
-2.07 %	-72.69 %	-304.63 %
(Mar 31 2019)		(Mar 31 2025)

News about Portage Biotech Inc Return on Assets ROA

Portage Biotech Inc. Faces Declining Performance and Financial Losses, Expands Evaluation of Strategic Alternatives to Rebound in Healthcare Sector

Portage Biotech Expands Strategic Alternatives Evaluation Amid Declining Performance and Financial Losses
Portage Biotech Inc., a leading biotechnology company, has announced its plans to expand the evaluation of strategic alternatives in a bid to improve its performance and financial standing. The company has recorded a decline in its share value by -4.65% in April 2024 and a cumulative net loss of $-19 million during the 12 months leading up to the fourth quarter of 2022. These figures have resulted in a negative return on assets (ROA) of -10.96%.
The healthcare sector has witnessed a significant difference in the performance of Portage Biotech Inc. compared to its peers. With 381 other companies in the same sector having a higher return on assets, Portage Biotech Inc. finds itself struggling to maintain competitiveness.
The decline in share value and the significant financial losses incurred by the company have prompted Portage Biotech Inc. to reevaluate its strategic alternatives. By expanding this evaluation, the company aims to identify measures that will lead to a turnaround in its performance and allow it to regain its competitive edge within the healthcare sector.
The decision to pause the clinical development of Adenosine has also impacted Portage Biotech Inc. s overall performance. Adenosine, a promising drug candidate, has the potential to make significant contributions to the company s future success. However, the decision to halt its clinical development suggests that the company needs to reevaluate its approach and prioritize alternative strategies.

Financial Statements
Portage Biotech Inc 's Assets	$ 2 million	PRTG's Balance sheet
Portage Biotech Inc 's Income	$ -7 million	Quarterly PRTG's Income Statement
PRTG's Income by Division		See PRTG's Income by Division

Annual Return On Assets	(Mar 31 2025) FY 2025	(Mar 31 2024) FY 2023	(Mar 31 2022) FY 2022	(Mar 31 2021) FY 2021	(Mar 31 2020) FY 2020
Y / Y Total Assets Change	-83.51 %	-82.8 %	28.53 %	-65.38 %	256.29 %
Total Assets in million	2	13	78	61	176
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-7	-105	-19	-17	-7
Annual Return On Assets	-304.63 %	-775.53 %	-24.43 %	-28.16 %	-4.11 %

PRTG's 5 Years Annual ROA >> Back to PRTG Management Effectiveness >> Compare PRTG ROA to its Competitors

More Return On Assets Ratios
PRTG's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PRTG's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PRTG's Competitors
Subscribers only: Roa for Portage Biotech Inc 's Suppliers
Subscribers only: Return On Assets for PRTG's Customers

You may also want to know
PRTG's Roi	PRTG's Inventory Turnover Ratio	PRTG's Growth Rates	PRTG's Dividend Comparisons
	PRTG's Profitability Ratios	PRTG's Asset Turnover Ratio	PRTG's Dividend Growth
PRTG's Roe	PRTG's Valuation Ratios	PRTG's Financial Strength Ratios	PRTG's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.